Shots:

• The P-II study involves assessing of LNP023 in PNH patients with active hemolysis despite treatment with eculizumab
• Results: improvements in hematological response and biomarkers of disease activity; 70% discontinued eculizumab and remained on LNP023 as monothx.- retaining Hb levels with no changes in biomarkers of disease activity and with no signs or symptoms of breakthrough hemolysis
• LNP023 is a potent and highly selective factor B inhibitor of the alternative complement pathway- currently in development for multiple renal conditions with complement system involvement. Additionally- the company is conducting an ongoing P-II study to assess LNP023 as monothx. for anti-C5 naïve PNH patients- with plans to initiate P-III study in late 2020

 Ref: Novartis | Image: Novartis